Published in Patient Care Law Weekly, May 13th, 2007
For the quarter ended March 31, 2007, total revenues of $1.2 million were equal to the total revenues for the quarter ended March 31, 2006. These revenues primarily reflect the amortization of up-front license fee payments from Laboratory Corporation of America(R) Holdings (LabCorp(R)) and, to a lesser extent, royalties on LabCorp's sales of PreGen-Plus(TM) (LabCorp's colon cancer testing service) and sales of Effipure(TM) units to LabCorp. Net loss for the quarter ended March 31, 2007 decreased to $1.9 million, or $0.07 per share, compared to a net loss...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Patient Care Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.